Modifications of nutrient selection induced by naloxone in rats

Total caloric intake and dietary self-selection of the three macronutrients protein, fat, and carbohydrate were examined in male rats maintained on a 6-h feeding schedule following the administration of the opioid antagonist naloxone HCl (0.1, 1.0, and 10.0 mg/kg IP). Total caloric intake (calculated as the sum of caloric intakes from each of the macronutrients) was decreased for up to 2 h following naloxone administration. By the end of the 6-h feeding period, however, no differences in total caloric intakes were observed as a function of naloxone injections. Examination of intakes of the individual macronutrients revealed that naloxone differentially affected fat, carbohydrate, and protein consumption. Across the 6-h feeding period, animals consumed less calories from the fat ration following all three doses of naloxone than after saline injections. Carbohydrate intake was decreased for up to 2 h following naloxone injections, but returned to control values by the end of the 6-h feeding period. Protein intake, in contrast to fat and carbohydrate intakes, did not vary as a function of naloxone administration. Results of the present experiment are contrasted with patterns of dietary self-selection observed following morphine administration.     

Differential effects of amphetamine and fenfluramine on dietary self-selection in rats

Daily caloric intakes and dietary self-selection of the three macronutrients, protein, fat and carbohydrate were examined in female rats following administration of d-amphetamine sulfate (0.0, 0.5, 1.0 and 2.0 mg/kg, IP) or fenfluramine hydrochloride (0.0, 1.5, 3.0 and 6.0 mg/kg, IP). Animals were maintained on ground Purina Chow or one of two self-selection regimes, one with a high-caloric fat ration (7.85 kcal/g) and the other with a fat ration isocaloric to the carbohydrate and protein rations (3.76 kcal/g). Animals received drug injections at the beginning of a daily 8-hour feeding period with nutrient intakes measured at 2, 4 and 8 hrs following injections. While both amphetamine and fenfluramine led to dose-related decreases in total caloric intakes, the two drugs resulted in different temporal patterns of feeding. Amphetamine produced its greatest effect on caloric intake during the first 2 hours of the feeding period, whereas fenfluramine suppressed caloric intake equivalently across the 8-hour feeding period. The two anorectic drugs also led to different patterns of nutrient choice. When animals were given the high-caloric fat ration, amphetamine selectively decreased fat intake while fenfluramine produced decreases in both protein and fat intakes, sparing carbohydrate intake. In contrast, when animals were given the isocaloric fat ration, amphetamine resulted in a general suppression of nutrient intakes while fenfluramine led to a sustained decrease in fat intake with a relative sparing of protein and carbohydrate consumption.     

Increased fat consumption induced by morphine administration in rats

Patterns of caloric intakes and dietary self-selection of the three macronutrients, protein, fat and carbohydrate were examined in male rats following the administration of morphine sulfate (0.0, 1.0, 10.0 and 20.0 mg/kg, IP). Animals were given access to either ground Purina Chow or one of two dietary self-selection regimes, one with a high-fat ration (7.8 kcal/g) and the other with a fat ration isocaloric to the carbohydrate and protein rations (3.8 kcal/g). Animals received morphine injections at the beginning of a six-hour feeding period and nutrient intakes were measured at 1,2,4 and 6 hours postinjection. Similar patterns of macronutrient choice were observed for both animals maintained on the high-fat regime and animals with access to the isocaloric components following morphine injections. As a function of morphine injections, animals on both self-selection regimes increased fat intake while suppressing carbohydrate intake and exhibiting little modifications in protein intake.     

Increased carbohydrate consumption by rats as a function of 2-deoxy-D-glucose administration

Dietary self-selection was examined following the administration of the glucoprivic agent, 2-deoxy-D-glucose (2-DG), in adult male rats given access to separate sources of the three macronutrients, protein, fat and carbohydrate. All animals received injections (IP) of saline, 250, 500 and 750 mg/kg 2-DG with nutrient intakes measured at 2, 4, 6 and 24 hrs following injections. Animals consumed significantly more carbohydrate at 4, 6 and 24 hrs after injections of 500 and 750 mg/kg 2-DG than after saline injections. In contrast, fat intake was significantly suppressed by all three doses of 2-DG at 2 hr, by 250 and 750 mg/kg 2-DG at 4 and 6 hrs, and by 750 mg/kg 2-DG at 24 hr after injections. Protein intake was significantly decreased by all three doses of 2-DG at 2 hr after injections. As a result of the increase in carbohydrate intake and complimentary decrease in fat intake following 2-DG injections, total caloric intake of animals given the self-selection regime was not modified as a function of drug administration. In comparison, rats given a single nutritionally complete diet (ground Purina Laboratory Chow) consumed significantly more calories following 2-DG administration than following saline injections. The ability of animals to make appropriate modifications in nutrient selection following regulatory challenges is discussed.     

Opioid receptor involvement in the adaptation to motion sickness in Suncus murinus.

The aim of the present study was to investigate an opioid receptor involvement in the adaptation response to motion sickness in Suncus murinus. Different groups of animals were treated intraperitoneally with either saline, morphine (0.1 and 1.0 mg/kg), naloxone (1.0, 10.0 and 5.0 mg/kg) or a combination of naloxone plus morphine in the absence or 30 min prior to a horizontal motion stimulus of 1 Hz and 40 mm amplitude. For the study of adaptation, different groups received saline on the first trial, and in subsequent trials (every 2 days) they received either saline, naloxone (1.0 and 10.0 mg/kg, i.p.) or morphine (0.1 mg/kg, i.p.) 30 min prior to the motion stimulus. Pretreatment with morphine caused a dose-related reduction in emesis induced by a single challenge to a motion stimulus. Pretreatment with naloxone alone did not induce emesis in its own right nor did it modify emesis induced by a single challenge to a motion stimulus. However, pretreatment with naloxone (5.0 mg/kg, i.p.) revealed an emetic response to morphine (P<.001) (1.0 mg/kg, i.p.) and antagonised the reduction of motion sickness induced by morphine. In animals that received saline or naloxone (1.0 mg/kg), a motion stimulus inducing emesis decreased the responsiveness of animals to a second and subsequent motion stimulus challenge when applied every 2 days for 11 trials. However, the animals receiving naloxone 10.0 mg/kg prior to the second and subsequent challenges showed no significant reduction in the intensity of emesis compared to the first trial. The data are revealing of an emetic potential of morphine when administered in the presence of a naloxone pretreatment. The administration of naloxone is also revealing of an additional inhibitory opioid system whose activation by endogenous opioid(s) may play a role in the adaptation to motion sickness on repeated challenge in S. murinus.     

Reduction of fat and protein intakes but not carbohydrate intake following acute and chronic fluoxetine in female rats.

Fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, leads to reductions in food intake and body weight and is under investigation as a possible treatment for obesity. Additionally, it has been suggested that fluoxetine administration could lead to a selective suppression in carbohydrate consumption. Because women more often than men seek weight reduction treatment, the present study examined the acute and chronic effects of fluoxetine on food intake, macronutrient selection, body weight, estrous cycle, and motor activity in female rats. Female Long-Evans rats were provided with separate sources of protein, fat and carbohydrate, and nutrient intakes were recorded following single (5.0, 10.0, and 20.0 mg/kg, IP) and chronic daily (10 mg/kg for 28 days) injections of fluoxetine. Acute and chronic administration of fluoxetine significantly reduced total caloric intake when compared to vehicle treatment. Moreover, fluoxetine significantly suppressed fat and protein intakes, but not carbohydrate intake following both acute and chronic drug administration. Animals chronically treated with fluoxetine gained significantly less weight than animals treated with vehicle. Chronic fluoxetine treatment did not significantly alter estrous cycle. However, in both fluoxetine- and vehicle-treated animals, total caloric intake, and carbohydrate and protein intakes were reduced and fat intake was increased when estrogen levels were high. Fluoxetine significantly reduced motor activity up to 4 h postinjection, and increased motor activity 24 h postinjection.     

Morphine selectively influences macronutrient intake in the rat

Dietary self-selection of the three macronutrients, protein, carbohydrate and fat, was examined in male rats following the administration of three doses of morphine sulphate: 10 mg, 15 mg, and 30 mg/kg body weight. Intakes of all three macronutrients were suppressed in a dose-dependent manner for a two-hour period following morphine administration. Both protein and carbohydrate intakes remained suppressed for a six-hour feeding period after morphine injections. In contrast, animals increased fat intake during the final four hours of the six-hour feeding period resulting in an overall increase in fat intake.     

The acoustic startle response as a measure of behavioral dependence in rats

A series of experiments was conducted to assess the sensitivity of the acoustic startle response to chronic morphine administration and naloxone-precipitated withdrawal. Rats were implanted with two subcutaneous pellets containing either 75 mg each of morphine or containing only placebo. In experiment 1, withdrawal induced by 0.05–0.2 mg/kg naloxone dose-dependently decreased the magnitude of the startle response. Physical dependence was confirmed by a naloxone-induced acute weight loss seen in morphine-implanted rats, but naloxone had no effect on startle or body weight in nondependent animals. In experiment 2, a modified procedure with fewer trials per session and fewer test days was employed. Naloxone (0.2 mg/kg) given 4–5 days after implantation induced large startle-response decreases in morphine-dependent rats while having no effect in placebo-implanted rats. Post-naloxone saline tests revealed no significant differences in startle between morphine and placebo groups. Startle scores were significantly higher in morphine-implanted rats than in placebo rats during a saline test given 3 days following pellet implantation. In a separate group of animals, however, acute IP injections of morphine from 0.3–10 mg/kg had no significant effect on startle amplitude. The effect of repeated pairings of withdrawal with the startle environment was assessed in experiment 3. Morphine-dependent rats startled significantly less if naloxone injections were given before the startle session than if they were administered 4 h later. Conditioned withdrawal effects, expressed during a final test session when all rats received saline, were observed for the body-weight measure but not for the startle response. These results suggest that the acoustic startle response may be a useful objective measure in evaluating physical dependence produced by substances of abuse.     

Evidence that physical dependence on morphine is mediated by the ventral midbrain

Rats were given daily injections of increasing doses of morphine sulfate (40-100 mg/kg, s.c.), for 4 days. Twenty hours after the last injection of morphine, the animals received bilateral injections of naloxone (1-10 micrograms) into the substantia nigra, ventral tegmental area or sites 2 mm rostral, caudal or dorsal to the site in the nigra. Withdrawal signs were monitored for 20 min after the intracerebral injection. Naloxone administered into the nigra in morphine-dependent rats produced dose-dependent significant increases in wet dog shakes, irritability to touch, teeth chattering, diarrhea and locomotion, compared to morphine-dependent animals that received injections of saline into the nigra. The injection of naloxone (3 micrograms) into the ventral tegmental area of morphine-dependent animals, produced irritability to touch and diarrhea, compared to morphine-dependent controls that received saline in this region of the brain. Significant differences in withdrawal signs were observed between morphine-dependent animals, that received injections of naloxone (3 micrograms) into the nigra and those that received naloxone (3 micrograms) into the ventral tegmental area or rostral or caudal sites. No differences between the substantia nigra and the dorsal sites were observed. However, withdrawal symptoms were produced by injections of naloxone into the substantia nigra and ventral tegmental area, even when the guide cannulae were angled to avoid penetration of sites dorsal to these regions of the brain. Naloxone, injected into the ventral midbrain of non-dependent animals, produced no signs of withdrawal. These studies suggest that the ventral midbrain mediates physical dependence on morphine.     

The effects of morphine on diet selection are dependent upon baseline diet preferences

It has been reported that morphine causes a selective increase in the intake of dietary fat. Because we have noted considerable variability among rats in their preferences for carbohydrate and fat, we reasoned that the effect of morphine on diet selection may differ in fat-preferring vs. carbohydrate-preferring rats. Male Sprague-Dawley rats were given ad lib access to separate sources of carbohydrate, fat and protein (Experiment 1), or to a carbohydrate/protein and a fat/protein diet (Experiment 2). After daily baseline intakes of the diets were determined, all rats were tested for feeding responses to subcutaneous injections of morphine (0, 2 and 10 mg/kg). Significant positive correlations were found between baseline daily intake of a given diet and the effect of morphine on the intake of that diet. Generally, morphine increased carbohydrate intake in carbohydrate-preferring rats, and increased fat intake in fat-preferring rats. These results suggest that the effect of morphine is to increase intake of a preferred diet rather than to increase intake of a specific macronutrient.     

Role of associative and nonassociative mechanisms in tolerance to morphine "anorexia"

To determine whether tolerance to morphine-induced anorexia involves associative mechanisms, rats were given chronic injections of morphine (Group 1, 10 mg/kg; Group 2, 20 mg/kg) in the presence of one compound cue on alternate days and injections of saline in the presence of another compound cue on the intervening days. After tolerance developed to the initial suppression of intake, three tests of Pavlovian conditioning were conducted. On the compensatory response test, in which saline injections were given in the presence of the morphine cue, only Group 2 showed a significant increase in milk intake. On the explicit unpairing test and the environmental specificity test, in which morphine injections were given in the presence of the saline cue or in an entirely different room, respectively, neither group showed a significant loss of tolerance. The failure to demonstrate cue-dependent tolerance in this paradigm may have been due in part to inadvertent temporal conditioning and in part to the rapid development of nonassociative tolerance.     

Central and peripheral contributions of endogenous opioid systems to nutrient selection in rats

The contribution of central and peripheral sites to opioid mediation of energy intake and dietary self-selection of the three macronutrients, protein, fat, and carbohydrate, was examined in male rats. Animals given access to either Purina Chow or a self-selection regime were injected with either the opioid antagonist, naltrexone (0.0, 0.1, 1.0, and 5.0 mg/kg, IP), or quarternary naltrexone (0.0, 0.1, 1.0, and 5.0 mg/kg, IP), an opioid antagonist that does not readily enter the central nervous system. Animals received injections at the beginning of an 8-h feeding period, and nutrient intakes were measured at 1, 2, 4, and 8 h postinjection. Naltrexone and its quarternary analogue differed in their effects both on total energy intake and macronutrient selection. Naltrexone led to significant decreases in total energy intake in animals on both dietary regimes, whereas quarternary naltrexone did not modify energy intake of animals given access to either diet. Naltrexone produced a sustained reduction in fat intake and initial decreases in carbohydrate and protein intakes. Quarternary naltrexone did not modify overall energy intake but did lead to modifications in nutrient choice. In contrast to naltrexone, quarternary naltrexone resulted in increased fat intake, decreased carbohydrate intake, and a small reduction in protein intake. These data suggest that both peripheral and central sites contribute to opioid effects on patterns of nutrient choice.     

Context- and cue-conditioned potentiation of acute morphine dependence and withdrawal

Single morphine injections induce a state of acute opioid dependence measured by an increase in naloxone potency to precipitate withdrawal. Repeated morphine exposure (daily/weekly intervals) results in further potentiation of naloxone potency, perhaps due to conditioning mechanisms. The current study tested the hypothesis that previously neutral stimuli could elicit a conditioned potentiation of the withdrawal response following acute bolus injections of morphine. Rats trained on an FR-15 schedule for food received five morphine injections (5.6 mg/kg) at daily intervals. Four hr after morphine injection on Conditioning Days (first 4 days), naloxone (1 mg/kg)-induced suppression of responding was paired either with operant context only, or with a tone/light conditioned stimulus (CS). On Test Day low dose naloxone (0.001-0.33 mg/kg) given 4-h post-morphine preceded the operant session. Rats exposed to naloxone repeatedly in the operant context without CS (Paired-Context Only) showed an increase in naloxone potency on Test Day relative to Unpaired Controls that received all morphine and naloxone in the home cage at a different time of day than operant testing. Rats exposed to the tone/light CS on Conditioning Days also showed a significant increase in naloxone potency relative to Unpaired Controls when the CS was represented on Test Day (Paired-CS), but not when the CS was omitted on the Test Day (Paired-CS/Test Context). Thus, conditioning processes appear to play a significant role in the early development of opioid dependence and withdrawal.     

Acute effects of morphine on Substance P concentrations in microdissected regions of guinea-pig brain

The present study investigated the effects of acute morphine treatment and of naloxone-induced morphine withdrawal on Substance P (SP) concentrations in microdissected regions of the guinea-pig brain. Guinea-pigs, which were treated with a single dose of morphine sulphate (15mg/kg s.c.), received naloxone hydrochloride (15mg/kg s.c.) after 2h. Control animals received injections of saline, saline and naloxone, or morphine and saline. Locomotor and behavioural activities were measured throughout the experiments. Animals were killed 0.5h after naloxone administration, brains were removed and SP-like immunoreactivity (SP-LI) was measured in microdissected regions using radioimmunoassay. Morphine significantly increased the concentration of SP-LI in the central nucleus of the amygdala, but reduced SP-LI overall in the mesencephalon. Guinea-pigs pretreated with morphine and then given naloxone to precipitate withdrawal showed no change in SP-LI concentrations in any brain region, compared with control animals, despite an increase in locomotor activity and other behaviours characteristic of opioid withdrawal in guinea-pigs.     

Effects of naloxone on morphine induced sedation and hyperactivity in the hamster

Three experiments investigated the effects of naloxone on morphine elicited changes in hamster locomotor activity. In Experiment 1, a prior subcutaneous injection of naloxone (0.4 mg/kg) converted morphine (15 mg/kg) elicited hypoactivity into hyperactivity: Compared with saline controls, naloxone pretreated animals were hyperactive following a subcutaneous injection of morphine. Experiment 2 investigated the effects of four doses of naloxone (0, 0.04, 0.1, 0.4 mg/kg) on morphine elicited hyperactivity. Results indicated that naloxone reversal of morphine elicited hyperactivity is directly related to dose of naloxone. In Experiment 3, naloxone (0.4 mg/kg) was administered one and two hours after a morphine injection. Compared with saline controls, morphine treated animals were hypoactive for approximately 40 minutes after each of the naloxone injections. Results are discussed in terms of a modified dual-action hypothesis.     

Conditioned flavor aversions for assessing precipitated morphine abstinence in rats.

Rats receiving twice-daily morphine injections acquired aversions to a saccharin solution which had been presented for 1 hr immediately prior to injections of naloxone. The degree of aversion was related to the maintenance dosage of morphine. Rats maintained on a regimen of daily saline injections did not show significant aversion to saccharin paired with naloxone, even at doses as high as 40 mg/kg. The sensitivity of the technique was such that significant aversions could be demonstrated in rats receiving doses of morphine as low as 1 mg/kg twice daily. It is suggested that conditioned flavor aversions provide a useful method for assessing the aversive quality of abstinence precipitated from low doses of morphine.     

Effects of chronic antenatal and postnatal administration of narcotics on naloxone-induced anorexia in preweanling rats

Previous studies have reported age-related changes in opiate receptors and in their response to narcotics during the process of normal growth of the brain. By inducing alterations in this developmental sequence, the present study attempted to provide correlates of the opiate receptor system with naloxone-induced anorexia. Offspring of mothers treated with morphine (7.5 mg/kg twice daily, s.c.) or saline during pregnancy, and infants from untreated mothers given morphine (5 mg/kg), naltrexone (10 mg/kg) or saline subcutaneously on postnatal days 1-5, were tested at days 10, 12 and 14 for deprivation-induced milk consumption following an acute dose of naloxone (1 or 5 mg/kg, i.p.). Naloxone reduced the food intake of 10- and 12-day old infants chronically treated with morphine postnatally. At age 14, naloxone reduced the food consumed by all the pretreatment groups, and pretreatment with morphine altered the dose-response curves for feeding modulation induced by naloxone. Naloxone had no effect on the food consumed by 10- or 12-day old offspring of mothers treated with morphine or saline, or on those age-groups that received naltrexone chronically or saline pretreatments postnatally. The observed changes occurred in the absence of gross malformations, drug-withdrawal symptoms and differences in activity. These results demonstrate that opiate receptors may participate in feeding.     

Anxiolytic-like effects of morphine and buprenorphine in the rat model of fear-potentiated startle: tolerance,cross-tolerance,and blockade by naloxone

Rationale Morphine and buprenorphine have analgesic and anxiolytic-like properties. While their analgesic effects have been well characterized, their anxiolytic-like properties have not. Objectives Effects of acute morphine and buprenorphine on the expression of acoustic fear-potentiated startle (FPS) and naloxone pretreatment were assessed. Effects of chronic morphine and buprenorphine on tolerance, cross-tolerance, and withdrawal were also examined. Materials and methods Fear-conditioned rats were given subcutaneous drug treatment immediately before testing for FPS. Experiment 1, rats were administered morphine (0.03, 0.25, 0.63, 2.5, or 10 mg/kg) or buprenorphine (0.004, 0.0075, 0.015, 0.03, or 0.25 mg/kg). Experiment 2, rats were given saline or naloxone (0.5 mg/kg) and 5min later given saline, morphine (2.5 mg/kg), or buprenorphine (0.03 mg/kg). Experiment 3, rats received once-daily injections of saline, morphine (10 mg/kg), or buprenorphine (0.25 mg/kg) for 7 days. Immediately before testing, saline-treated rats were given saline, morphine (2.5 mg/kg), or buprenorphine (0.03 mg/kg), morphine-treated rats were given morphine (2.5 mg/kg) or buprenorphine (0.03 mg/kg), and buprenorphine-treated rats were given buprenorphine (0.03 mg/kg) or morphine (2.5 mg/kg). Tolerance and cross-tolerance in analgesia were assessed via the tail-flick test, as were naloxone-precipitated withdrawal. Results Morphine and buprenorphine had parallel dose–response curves in blocking FPS, with buprenorphine 40 times more potent than morphine. Naloxone reversed these effects. Morphine and buprenorphine showed tolerance and cross-tolerance in their anxiolytic-like and analgesic effects. Chronic buprenorphine produced less withdrawal than chronic morphine. Conclusions Cross-tolerance between morphine and buprenorphine suggests a common receptor mediating their anxiolytic-like and analgesic effects.     

Induction of tolerance and withdrawal in rats receiving morphine in the spinal subarachnoid space.

Rats implanted with chronic catheters in the spinal subarachnoid space were given twice daily injections for 7 days of morphine sulfate, either intrathecally into the lumbar subarachnoid space (15 or 50 microng) or i.p. (20 mg/kg). The development of tolerance, as manifested in a reduction of the analgetic efficacy of these injections on the hot plate and tail flick, occurred in a dose dependent fashion over a period of 7 days. At this time, injections of i.p. morphine into animals which had received spinal morphine and vice versa revealed the existence of a two way cross tolerance between spinal and systemically administered morphine. Injection of naloxone into the spinal cord of animals exposed to i.p. morphine or conversely, i.p. naloxone in animals tolerant to intrathecal morphine, yielded a hyperreflexia and extreme sensitivity to handling. Other signs commonly observed in percipitated withdrawal, however, such as wet shakes and weight loss, were not observed.     

Endogenous opioids are involved in morphine and dipyrone analgesic potentiation in the tail flick test in rats

The combined administration of low doses of opiates with non-steroidal anti-inflammatory drugs can produce additive or supra-additive analgesic effects while reducing unwanted side effects. We have recently reported that co-administration of morphine with dipyrone (metamizol) produces analgesic potentiation both in na?ve and in morphine-tolerant rats. The purpose of this work was to determine the role of opioids on the acute potentiation observed between morphine and dipyrone i.v. in the rat tail flick test. To do this, two experiments were done. In the first one, naloxone was administered 10 min before morphine (3.1 mg/kg), dipyrone (600 mg/kg) or their combination at the same doses. Control animals received saline instead of naloxone. In the second experiment, naloxone (or saline) was given 2 min after reaching the maximal peak effect with each individual analgesic treatment. When naloxone was i.v. administered prior to analgesics, it completely blocked morphine effects, partially prevented morphine/dipyrone antinociception and delayed dipyrone-induced nociception. At 3.1 mg/kg, naloxone produced an increased nociception. When naloxone was given after analgesics, it dose-dependently blocked the effects of morphine alone and in combination with dipyrone but with different potency in each case. As to dipyrone, naloxone delayed the time to antinociceptive peak effect. Taken together, these results support the notion that endogenous opioids are involved in the analgesic potentiation observed with the combination of morphine plus dipyrone.